Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-Human EGFR/ERBB1/HER1 Antibody (11F8), PE

Catalog #:   FHB86932 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG2a, kappa
Applications: ELISA, FCM
Accession: P00533
Overview

Catalog No.

FHB86932

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Conjugation

PE

Target

Epidermal growth factor receptor, 2.7.10.1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, EGFR, ERBB, ERBB1, HER1

Concentration

1.23 mg/ml

Endotoxin level

Please contact with the lab for this information.

Accession

P00533

Applications

ELISA, FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.

Stability and Storage

Store at 4°C for 12 months. Protect from light. Do not freeze.

Clone ID

11F8

Data Image
References

Effects of Ganoderma spent substrate containing with polysaccharides and triterpenoids on the growth performance, antioxidant capacity and immunity level of chickens., PMID:40532998

Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer., PMID:40532664

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment., PMID:40526090

Comparison of Intrapatient Variability of IR-Tacrolimus Versus LCP-Tacrolimus in a Cohort of Lung Transplant Recipients., PMID:40525559

Safety and Efficacy of the First Subcutaneous ICI, Envafolimab, in the Treatment of Advanced Lung Cancer Patients: A Real-World Study., PMID:40524516

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation., PMID:40523897

Precision medicine approaches to CNS metastatic disease., PMID:40518193

Engineered MAP30ER: A plant toxin-derived platform for EGFR-Targeted delivery of protein and chemotherapeutic payloads., PMID:40517671

Nanobodies targeting EGFR provide insight into conformations stabilized by glioblastoma mutations., PMID:40516870

A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC., PMID:40516821

Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study., PMID:40514709

Structural insights into the activation and inhibition of the ADAM17-iRhom2 complex., PMID:40512800

Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type., PMID:40512776

LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC., PMID:40511820

Unraveling Botulinum Neurotoxin A Light-Chain-Induced Signaling Pathways: A Phosphoproteomic Analysis in a Controlled Cellular Model., PMID:40507977

Facial Skin With Conspicuous Enlarged Pores Closely Related to Severity of Facial Acneiform Rash and Therapeutic Effects of EGFR Inhibitors in RAS Wild-Type Metastatic Colorectal Cancer: Ancillary Analysis of FAEISS Study (NCCH1512)., PMID:40503645

Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection., PMID:40503012

Advances in cancer research on FUT8Molecular mechanisms and clinical applications., PMID:40497775

Exploring cellular plasticity and resistance mechanisms in lung cancer: Innovations and emerging therapies., PMID:40496071

Effects of concurrent HER2-directed therapy on development of cerebral radionecrosis after stereotactic radiotherapy: a systematic review., PMID:40493045

Predictive power of tertiary lymphoid structure for prognosis and neoadjuvant chemotherapy response in HER2-positive breast cancer., PMID:40489875

An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti-Angiogenic Agents for Therapy: A Case Report., PMID:40488279

Epidermal Growth Factor Receptor (EGFR) Downregulation by Cetuximab in Salivary Duct Carcinoma: A Case Report., PMID:40486390

Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction., PMID:40484132

Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers., PMID:40480221

Aptamers as therapeutic targets: prospects and progress in the treatment of cancers., PMID:40479828

Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial., PMID:40473437

Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China., PMID:40472040

Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors., PMID:40469307

TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis., PMID:40468999

Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report., PMID:40468744

HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer., PMID:40468352

Retrospective stratified analysis of resistance mechanisms to anti-EGFR therapy in mCRC using tumor tissue samples., PMID:40467730

ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib., PMID:40466026

Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer., PMID:40464376

Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future., PMID:40463417

Mechanisms of resistance to antibody-drug conjugates in cancers., PMID:40460510

First-line treatment with a combination of immunotherapy, anti-EGFR monoclonal antibodies, and chemotherapeutics for unresectable left KRAS/BRAF wild-type microsatellite-stable colorectal cancer: a case report., PMID:40460045

Targeting endothelial growth factor receptor in thyroid cancer: current concepts and future directions., PMID:40457134

Epidermal growth factor receptor specific immunotherapy for SHH medulloblastoma tested in an in vitro blood-brain barrier-model., PMID:40456204

Cutaneous adverse effects of combination epidermal growth factor receptor inhibitor and immune checkpoint inhibitor cancer therapy., PMID:40455297

T-cell activation enhances anti-HER2-mediated antibody-dependent cellular cytotoxicity in gastric cancer., PMID:40455140

Tocilizumab-Based Treatment of Microvascular Inflammation in Kidney Transplant Recipients: A Retrospective Study., PMID:40454296

A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models., PMID:40452841

Contribution of Anti-type IV Collagen Antibodies From Kidney Basement Membrane to Increased Level of Urinary Immunoglobulin G in Nephritis Patients: A Comparison of Nephritic and Healthy Urine., PMID:40452732

Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations., PMID:40448190

Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer., PMID:40446773

Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency., PMID:40445758

[Research progress on the mechanisms of resistance to cetuximab targeted therapy in head and neck squamous cell carcinoma]., PMID:40443385

Safety and efficacy of sirolimus combined with cyclosporine in primary membranous nephropathy: a randomized controlled trial., PMID:40442735

Datasheet
$ 216
Product specifications
50 T 216 100 T 354

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human EGFR/ERBB1/HER1 Antibody (11F8), PE [FHB86932]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only